Acutaas Chemicals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹393Cr
- +42.9% YoY
- +28.4% QoQ
- Net profit
- ₹106Cr
- +135.6% YoY
- +47.2% QoQ
- Margin
- 38%
- +13 pp YoY
- +7 pp QoQ
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years.
From Acutaas Chemicals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16).
- CDMO business is projected to cross INR 1,000 crores revenue by FY 2028, driven by multiple validated products and new contracts (Page 12, 17).
- Battery chemical segment, especially products like vinyl carbonate (VC) and fluoroethylene carbonate (FEC), is in early stages with capacity and contracts in place; further products are planned for commercialization in mid-FY 2027 onwards (Page 8, 16).
- Semiconductor chemical verticals (including Baba Fine Chem and Indichem JV) are expected to contribute meaningfully by 2028 with high EBITDA margins (Page 13, 16).
2 more points from Acutaas Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex.
- Indichem joint venture (South Korea) investment: INR 130 crores invested so far out of total INR 200 crores announced; capex progressing as per plan; additional investment possible this quarter.
- Second phase capex part of the INR 220 crore plan.
- Ankleshwar plant utilization currently at 40%; growth till FY '28 expected with possible incremental pharma intermediate capex after 1.5 years based on market conditions.
2 more points from Acutaas Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has good visibility of contracts for FY '27 and beyond, expecting fast scaling of its business.
- For the additives business, there are fixed pricing contracts in place with variability linked to raw materials and currency.
- The anticancer CDMO segment has long-term supply contracts, with projections extending through FY '28.
- Four new CDMO products validated in the current financial year are expected to start contributing from FY '27.
- Sampling and validation for additional CDMO products are underway, reinforcing a strong pipeline.
- Battery chemical orders for VC and FEC products are already in hand with good revenue visibility for FY '27.
- Two additional battery chemical products are expected to contribute to revenues starting mid-FY '27.
2 more points from Acutaas Chemicals Ltd's call on order book
Create a free account to keep reading this call
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Acutaas Chemicals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 393 | 275 | +42.9% | 306 | +28.4% |
| Operating profit (EBITDA) | 151 | 69 | +118.8% | 95 | +58.9% |
| Operating margin | 38% | 25% | +13 pp | 31% | +7 pp |
| Profit before tax | 145 | 63 | +130.2% | 96 | +51% |
| Net profit (PAT) | 106 | 45 | +135.6% | 72 | +47.2% |
| EPS (₹) | 13.19 | 5.49 | +140.3% | 8.82 | +49.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Acutaas Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q3 FY26 results?
Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
